Healthy Skepticism Library item: 13479

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Cole A.
Drug industry anxious about scrapping price regulation scheme
BMJ 2008 Mar 29; 336:(7646):686
http://www.bmj.com/cgi/content/extract/336/7646/686-a

Abstract:

Almost half (46%) of the United Kingdom’s drug companies expect to cut back on clinical trials in the coming year because of continued uncertainty about future arrangements for pricing drugs.

In a survey of more than 100 companies earlier this month on behalf of the Association of the British Pharmaceutical Industry and the Confederation of British Industry three quarters said they had little confidence in the current UK market environment, and 83% expected things to get worse in the next year.

The survey also showed that 30% of drug companies expect to cut staff in the next year, and more than a third expect to reduce research and development and investment in buildings and equipment. Two in five anticipated cutting back on manufacturing in the UK.

Despite this, almost two thirds thought their own business would grow in the coming year, and 43% thought their performance would improve. But nearly . . .